Mariusz Piotrowski
Medical University of Lublin
14 Papers
36 Citations
Mariusz Piotrowski is an academic researcher from Medical University of Lublin. The author has contributed to research in topics: Internal medicine & Population. The author has an hindex of 5, co-authored 13 publications.
Chat about Author
Papers
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
Dae Hyun Yoo,Paweł Hrycaj,Pedro Miranda,Edgar Ramiterre,Mariusz Piotrowski,Sergii Shevchuk,Volodymyr Kovalenko,Nenad Prodanovic,Mauricio Abello-Banfi,Sergio Gutierrez-Ureña,Luis Morales-Olazabal,Michael L. Tee,Renato Jimenez,Omid Zamani,Sang Joon Lee,HoUng Kim,Won Park,Ulf Müller-Ladner +17 more
TL;DR: CT-P13 demonstrated equivalent efficacy to INX at week 30, with a comparable PK profile and immunogenicity, in active rheumatoid arthritis patients with inadequate response to methotrexate treatment.
675
The Relationship between Hematological Markers of Systemic Inflammation (Neutrophil-To-Lymphocyte, Platelet-To-Lymphocyte, Lymphocyte-To-Monocyte Ratios) and Ultrasound Disease Activity Parameters in Patients with Rheumatoid Arthritis.
TL;DR: NLR and PLR are associated with US disease activity parameters and may serve as reliable, inexpensive markers, with prognostic significance in RA.
47
Prospective assessment of cardiovascular risk parameters in patients with rheumatoid arthritis.
TL;DR: During the 6-year course of established RA, significant exacerbation of atherosclerosis was found, revealed by higher cIMT, and a careful monitoring should be applied to patients with atherosclerotic plaques and of male gender due to higher burden of CV risk.
FRI0143 A randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P13 to infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis
Dae-Hyun Yoo,Pedro Miranda,Mariusz Piotrowski,Edgar Ramiterre,Volodymyr Kovalenko,Nenad Prodanovic,Michael L. Tee,Sergio Gutierrez-Ureña,Renato Jimenez,Omid Zamani,Sang Joon Lee,HoUng Kim,Won Park,Ulf Müller-Ladner +13 more
TL;DR: CT-P13 was well tolerated, with an efficacy and safety profile comparable to that of infliximab up to week 30, and are equivalent in terms of ACR20 in patients with RA.
10
THU0158 Inhibition of Radiographic Progression and Its Association with Clinical Parameters in RA Patients Treated with CT-P13 and Innovator Infliximab in PLANETRA Study
D.-H. Yoo,Won Park,Pedro Miranda,Mariusz Piotrowski,Edgar Ramiterre,Sergii Shevchuk,Asta Baranauskaite,S. Lee,Ulf Müller-Ladner +8 more
TL;DR: Patients treated with CT-P13 showed a comparable radiographic progression as compared to those treated with INX at week 54, and the ADA and clinical parameters such as ACR20, IgM RF, and anti-CCP showed tendency of association with radiography progression.
7